TH87137A - Vaccine composition - Google Patents

Abstract

DC60 (30/05/50) The invention here relates to virus vectors. Which includes oligonucleotides Several batches that encode the HIV polypeptide, more specifically, are When the vectors of these viruses are specifically adinoviruses, they are adenoviruses of non-human primates, such as monkey adinoviruses. More specific is Specifically, the adinovirus of chimpanzees, this invention relates to adinovirus vectors. This includes an HIV polynucleotide sequence that encodes many different HIV antibodies, for example two or three or more HIV antibodies. This invention also involves How to prepare virus vectors, virus vectors created in these ways? And the use of vectors in Medical treatment, especially vaccination for prevention or treatment of disease The invention here relates to virus vectors. Which includes oligonucleotides Several batches that encode the HIV polypeptide, more specifically, are When the vectors of these viruses are specifically adinoviruses, they are adenoviruses of non-human primates, such as monkey adinoviruses. More specific is Specifically, the adinovirus of chimpanzees, this invention relates to adinovirus vectors. This includes an HIV polynucleotide sequence that encodes many different HIV antibodies, for example two or three or more HIV antibodies. This invention also involves How to prepare virus vectors, virus vectors created in these ways? And the use of vectors in Medical treatment, especially vaccination for prevention or treatment of disease

Claims (20)

1. An adenovirus vector composed of a single polynucleotide or multiple polynucleotides that encoding the RT, Nef, and Gag immunogenic signals of HIV, or at least their immunogenic derivatives or incomplete portions, arranged so that they are transcribed in the Gag, RT, Nef sequence. 2. An adenovirus vector under claim 1 where the RT is truncated. 3. An adenovirus vector under claim 1 or 2 where the Nef is truncated. 4. An adenovirus vector according to any one of claims 1 through 3, where Gag will be only p17 and p24. 5. An adenovirus vector under one of the preceding claims where a single polynucleotide or multiple polynucleotides of HIV are of a size such that the total vector size is between 90 and 100% of the viral size. 6. An adenovirus vector under one of the preceding claims, whereby this virus is a non-human primate adenovirus. 7. The adenovirus vector under claim 6, whereby this virus is the chimpanzee adenovirus. 8. The adenovirus vector according to claim 7, where this adenovirus is selected from pan 5, 6, 7, and 9. 9. The adenovirus vector according to claim 8, where this adenovirus is pan 6. 10. The adenovirus vector according to claim 8, where this adenovirus is pan 7. 11. An adenovirus vector under any of the preceding claims in which the virus is defective in reproduction. 12. An adenovirus vector according to one of the preceding claims, from which regions E1 and E3 have been removed. 13. An adenovirus vector under one of the preceding claims in which the polynucleotide sequence encoding the HIV antigen is arranged in a fused manner. 14. Chimpanzee adenovirus is composed of the following polynucleotides: P17, p24 (codon optimized) Gag - p66 RT (codon optimized) - truncated Nef; truncated Nef - p66 RT (codon optimized) - p17, p24 (codon optimized) Gag; truncated Nef - p17, p24 (codon optimized) Gag - p66 RT (codon optimized); p66 RT (codon optimized) - p17, p24 (codon optimized) Gag - truncated Nef; p66 RT (codon optimized) - truncated Nef - p17, p24 (codon optimized) (optimized by Codon) Gag; p17, p24 (optimized by Codon) Gag - Nef with truncated ends - p66 RT (optimized by Codon) 15. The adenovirus vector according to claim 14, where this adenovirus is Pan 6 or Pan 7, provided that when the adenovirus is Pan 6, the construct is not p66 RT (ideal) - trNef - p17, p24 (ideal) Gag. 16. An immunological component comprising a viral vector as per one of the preceding claims and a pharmacologically acceptable carrier or adjuvant. 17. The use of adenovirus vectors under any of the claims 1 through 15 in the manufacture of drugs for the treatment or prevention of HIV infection. 18. Any of the methods for preparing vectors under claims 1 through 15, which include the following steps: a) administration of the adenovirus vector; b) administration of a plasmid containing a viable HIV immunogenic sequence linked to a suitable inducer; c) infection of cells with both the plasmid and the vector; d) allowing sufficient time for recombination to occur; and e) recovery of the recombinant viral vector containing the HIV immunogenic sequence. 19. A fused protein expressed by a vector pursuant to any of claims 1 through 15. 20. Fusion proteins under patent claim 19 that are generated within the human body.